GlassScriptPhysician profile
Sara J Pickett
NPI 1063464105
$6,693.26
in general payments reported to CMS, 2019-2025
23 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $1,316 · 2023: $1,657 · 2024: $1,926 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,865 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,864.88 |
| Education | $107.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $961.23 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $822.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $809.09 | 2021-2025 | |
| Janssen Biotech, INC. | $707.26 | 2021-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $536.57 | 2021-2025 | |
| Leo Pharma INC. | $442.48 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $366.66 | 2023-2025 | Zoryve |
| Ucb, INC. | $339.84 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $331.81 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $298.50 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $256.72 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $180.48 | 2022-2024 | Blu-U |
| Pfizer INC. | $171.57 | 2021-2024 | |
| Dermavant Sciences, INC. | $79.34 | 2023-2024 | Vtama |
| Kyowa Kirin, INC. | $76.46 | 2022-2024 | Poteligeo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $74.95 | 2023-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.12 | 2022-2023 | Spevigo |
| Organon LLC | $48.37 | 2025 | Vtama |
| Almirall LLC | $38.76 | 2023 | Klisyri |
| Biofrontera INC. | $27.16 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Sanofi-Aventis U.S. LLC | $24.95 | 2021 | |
| Janssen Scientific Affairs, LLC | $24.81 | 2022 | |
| Medtronic, INC. | $15.94 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Pickett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.